Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor ...
April 01 2019 - 8:00AM
- Data from cohort 2 of the innovaTIL-01 study
support polyclonal approach necessary to treat metastatic melanoma
-
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
data from an investigation of the persistence and diversity of
circulating T cells from metastatic melanoma patients from the
innovaTIL-01 (C-144-01) study receiving lifileucel TIL therapy.
Results from an analysis of the persisting T cell clones
circulating 42 days following infusion, as compared to the initial
TIL product, demonstrated two phenomena: first, that TIL product
from 100 percent of the evaluated patients in Cohort 2 of the
innovaTIL-01 trial are persisting in circulation at 42 days
post-infusion, and second, that each patient has a unique TIL
product with almost no overlap between patients for expanding
clones in the human body observed post-infusion. Furthermore, the
small number of overlapping clones between a few patients were not
associated with a clinical response. The uniqueness of the clonal
profiles associated with response highlights the challenge of
identifying a few T cell receptors as mediators of activity and
supports using a polyclonal product such as the Iovance bulk TIL to
treat high mutational load solid tumors.
“Investigation of pharmacokinetics of lifileucel TIL in
metastatic melanoma patients demonstrates excellent persistence of
lifileucel 42 days post-infusion. In addition, the ability of
lifileucel TIL therapy to generate responses in melanoma appears to
be the result of each patient’s specific populations of their TIL
product targeting the patient’s unique mutated tumor antigens”
commented Maria Fardis, Ph.D., MBA, president and chief executive
officer of Iovance. “The results of this study suggest that
high mutational load solid tumors such as melanoma are unlikely to
be effectively treated with products against a single or a small
number of antigens, implying a potential need for a patient
specific, polyclonal product such as Iovance’s TIL product
lifileucel.”
Identification of specific cancer-associated antigens
responsible for an antitumor immune response continues to be an
area of active research.1,2 The ability of autologous TIL therapy
to respond to the unique cancer antigens present in each individual
patient may be a factor in the response rates observed with
lifileucel treatment.
Study results were detailed in a late-breaking poster
presentation, “Persistence of cryopreserved tumor-infiltrating
lymphocyte product lifileucel (LN-144) in C-144-01 study of
advanced metastatic melanoma,” at the American Association for
Cancer Research (AACR) 2019 Annual Meeting. The presentation
abstract and additional information is available on the AACR
conference website at http://www.aacr.org.
Additional information about the registration-enabling
innovaTIL-01 (C-144-01) study of lifileucel in advanced melanoma is
available at https://clinicaltrials.gov/ct2/show/NCT02360579.
- Robbins PF, et al., Mining exomic sequencing data to identify
mutated antigens recognized by adoptively transferred
tumor-reactive T cells. Nature Medicine. 2013 Jun;19(6):747-52.
doi: 10.1038/nm.3161.
- Lu YC, et al., Efficient identification of mutated cancer
antigens recognized by T cells associated with durable tumor
regressions. Clinical Cancer Research. 2014 Jul 1;20(13):3401-10.
doi: 10.1158/1078-0432.CCR-14-0433.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize lifileucel, an
autologous cell therapy product using TIL technology that amplifies
the body’s own immune response to eradicate solid tumors or attack
blood cancers. The company is currently conducting the pivotal
study innovaTIL-01 in patients with metastatic melanoma. In
addition, the company’s TIL therapies are being investigated for
the treatment of patients with locally advanced, recurrent or
metastatic cancers including cervical, head and neck, and non-small
cell lung cancer. For more information, please visit
www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “suggest,”
“imply,” “supports,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. The forward-looking statements include,
but are not limited to: risks and uncertainties relating to the
success, timing, projected enrollment, manufacturing capabilities,
and cost of our ongoing clinical trials and anticipated clinical
trials for our current product candidates (including both
Company-sponsored and collaborator-sponsored trials in both the
U.S. and Europe), such as statements regarding the timing of
initiation and completion of these trials; the implications of the
Company’s clinical, correlative, and pre-clinical research
activities; the timing of and our ability to obtain and maintain
U.S. Food and Drug Administration (“FDA”) or other regulatory
authority approval of, or other action with respect to, our product
candidates; the strength of Company’s product pipeline; the
successful implementation of the Company’s research and development
programs and collaborations; the acceptance by the market of the
Company’s product candidates, if approved; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such
statements. Actual results may differ from those set forth in
this press release due to the risks and uncertainties inherent in
the Company’s business, including, without limitation:
investigational research results may not be supported by later
studies; the preliminary clinical results, including efficacy and
safety results, from ongoing Phase 2 studies may not be reflected
in the final analyses of these trials, including new cohorts within
these trials, and may not be supportive of product approval; the
FDA or other regulatory authorities may potentially delay the
timing of their approval of, or other action with respect to, the
Company’s product candidates; the Company’s ability to address FDA
or other regulatory authority requirements relating to its clinical
programs and registrational plans, such requirements including, but
not limited to, clinical and safety requirements as well as
manufacturing and control requirements; risks related to the
Company’s accelerated FDA review designations; and the ability of
the Company to manufacture its therapies using third party
manufacturers. A further list and description of the
Company’s risks, uncertainties and other factors can be found in
the Company’s most recent Annual Report on Form 10-K and the
Company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or www.iovance.com. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024